- Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian . . .
Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody–drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian cancer in the United
- ELAHERE® (mirvetuximab soravtansine-gynx) | HCP Website
Learn more about ELAHERE® (mirvetuximab soravtansine-gynx) For US healthcare professionals Please see Full Prescribing Information, including Boxed WARNING
- FDA approves mirvetuximab soravtansine-gynx for FRα positive, platinum . . .
On March 22, 2024, the Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc [now a part of AbbVie]) for adult patients with FRα positive,
- Mirvetuximab soravtansine - Wikipedia
Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer [1][4] Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate [4][5]
- Efficacy and Safety of Mirvetuximab Soravtansine in Patients With . . .
Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor α (FRα) SORAYA is a single-arm, phase II study evaluating efficacy and safety of MIRV in patients with PROC
- Mirvetuximab Soravtansine-Gynx Approved for Ovarian Cancer
Platinum-resistant ovarian cancer has proven difficult to treat, but with the Food and Drug Administration’s recent full approval of mirvetuximab soravtansine-gynx (Elahere), some people in this situation now have a new treatment option
- Mirvetuximab soravtansine-gynx (intravenous route)
Mirvetuximab soravtansine-gynx injection is used to treat folate receptor-alpha (FRa) positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have received 1 to 3 previous treatments
- Mirvetuximab Soravtansine
Mirvetuximab soravtansine is given when ovarian cancer has returned or spread to other parts of the body and is no longer responding to platinum-based chemotherapy
|